Serina enters $25M equity purchase agreement with Roth Principal Investments

Serina Therapeutics, Inc.

Up to $25M of new common stock can be sold to Roth Principal over 36 months at 3-7% discount to VWAP.
Sales are at Serina's sole discretion; no obligation to sell; proceeds for working capital.
Exchange cap of 5,077,554 shares (19.99% of outstanding) unless price >= $2.7695 or stockholder approval.
Roth Principal barred from short sales; Serina pays $100K legal fees plus $7.5K/quarter.
Registration rights agreement filed; Compass Point engaged as qualified independent underwriter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.